期刊文献+

COVID-19继发肺纤维化的病因病机及治则治法探讨 被引量:11

Study on Etiology and Pathogenesis in the Treatment of COVID-19 Secondary Pulmonary Fibrosis
暂未订购
导出
摘要 新型冠状病毒感染肺炎(Corona Virus Disease 2019,COVID-19)致病力强,疾病进展迅速,部分患者常遗留有肺纤维化情况,痰瘀阻络、气阴耗伤为COVID-19继发肺纤维化的病机关键,早期介入,治疗前移,活血化痰,固护正气,改善肺泡炎和微循环障碍,减少炎性渗出,减轻肺部病灶损害,使其得到充足的供血和营养,助肺脏恢复其功能,一方面有助于COVID-19疾病尽快恢复,另一方面也可降低COVID-19继发肺纤维化的风险,加快已成肺纤维化的好转速度,对于提高COVID-19患者的疗效和治愈出院后的生活质量具有重大意义。 The new corona virus pneumonia(Corona Virus Disease 2019,COVID-19)disease is highly pathogenic and the disease progresses rapidly.Some patients are often left with pulmonary fibrosis collateral blocked by phlegmstasis and impairment of Qi and yin are the key pathogenesis of pulmonary fibrosis secondary to covid-19.The reach early intervention and treatment,invigorate the circulation of phlegm,solid protection of vital Qi,alveolar inflammation and improve micro-circulation,reduce inflammatory exudation and reduce damage to lung lesions,with adequate blood supply and nutrition,helps the lungs to recover its functions,on the one hand,help COVID-19 disease to recover as soon as possible,on the other hand also can reduce the risk of COVID-19 secondary pulmonary fibrosis,to speed up is improvement of pulmonary fibrosis,to improve the therapeutic efficacy of COVID-19 patients and quality of life is of great significance to heal after discharge.
作者 田淼 余思邈 王仲霞 景婧 王丽苹 王立福 孙永强 许文涛 桑秀秀 王睿林 TIAN Miao;YU Simiao;WANG Zhongxia;JING Jing;WANG Liping;WANG Lifu;SUN Yongqiang;XU Wentao;SANG Xiuxiu;WANG Ruilin(The 5th Medical Centre of Chinese PLA General Hospital,Beijing 100039,China)
出处 《中医药临床杂志》 2020年第5期822-825,共4页 Clinical Journal of Traditional Chinese Medicine
基金 国家自然科学基金面上项目(No.81673806) 军队生物安全建设计划项目(No.A3704041902-02)。
关键词 新型冠状病毒 新型冠状病毒感染肺炎 肺纤维化 中医药治疗 2019-nCoV COVID-19 Pulmonary fibrosis TCM therapy
  • 相关文献

参考文献17

二级参考文献157

共引文献2260

同被引文献276

引证文献11

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部